Northwest Therapies Trauma Psilocybin Study Compassionate Use Study
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The on-boarding of unregulatable trauma in the United States has reached 20%, which1/5 of the
population. A population of this magnitude, by definition has reached an epidemic
classification. The population with chronic illness as stated: PTSD, Chronic Depression, MS,
HIV, and SARS-CoV-2- Long Haulers Syndrome. These chronic illness with unregulated trauma
create an unstable portion of the population. Psychiatrists have testified before congress
that the SSSRI medications are not functional cures and are not working for patients.
Psilocybin micro-dosing is proving to shave back the highjacked nervous system, stopping
ruminating neurotransmitter. The body has a natural path to stop these thoughts by a
neurotransmitter called serotonin This is the most famous neurotransmitter Serotonin, is very
similar to the plant medicine family of psilocybin, Serotonin and psilocybin work very
similarly with the 5h2A receptor in the human cortex ( the outer cortex of the brain ).
Micodosing 1 gram to 1/5 grams of psilocybin helps shave back the highjacked nervous system
known as the diagnosis (SSD) Somatic Symptom Disorder. This research is believed accurate by
proof on previous studies to reverse back the somatic feelings resulting from the trauma of
the individuals who are on boarding chronic diseases of PTSD, Chronic Depression, MS, HIV,
and SARS-CoV-2- Long Haulers Syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
NWTraumatherapies
Collaborators:
Imperial College London Johns Hopkins University World Health Organization